References
L. Aaron, D. Saadoun, I. Calatroni, O. Launay, N. Memain, V. Vincent , et al. , et al.. 2004. Tuberculosis in HIV-Infected Patients: A Comprehensive Review Clinical Microbiology and Infection 10: 388 - 98 (PubMed)
F. Adatu, R. Odeke, M. Mugenyi, G. Gargioni, E. McCray, E. Schneider and D. Maher. 2003. Implementation of the DOTS Strategy for Tuberculosis Control in Rural Kiboga District, Uganda, Offering Patients the Option of Treatment Supervision in the Community, 1998-1999 International Journal of Tuberculosis and Lung Disease 7: S63 - 71 (PubMed)
H. Albert, A. Heydenrych, R. Brookes, R. J. Mole, B. Harley, E. Subotsky , et al. , et al.. 2002. Performance of a Rapid Phage-Based Test, FASTPlaqueTBTM, to Diagnose Pulmonary Tuberculosis from Sputum Specimens in South Africa International Journal of Tuberculosis and Lung Disease 6: 6 529 - 37 (PubMed)
H. Albert, A. Trollip, T. Seaman and R. J. Mole. 2004. Simple, Phage-Based (FASTPlaque) Technology to Determine Rifampicin Resistance of Mycobacterium tuberculosis Directly from Sputum International Journal of Tuberculosis and Lung Disease 8: 1114 - 19 (PubMed)
P. Andersen. 2001. TB Vaccines: Progress and Problems Trends in Immunology 22: 160 - 68 (PubMed)
Anderson, R. M., and R. M. May. 1991. Infectious Diseases of Humans: Dynamics and Control. Oxford, U.K.: Oxford University Press.
K. Andries, P. Verhasselt, J. Guillemont, H. W. Gohlmann, J. M. Neefs, H. Winkler , et al. , et al.. 2004. A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium Tuberculosis Science 307: 223 - 27 (PubMed)
E. Asamoah-Odei, J. M. Garcia Calleja and J. T. Boerma. 2004. HIV Prevalence and Trends in Sub-Saharan Africa: No Decline and Large Subregional Differences Lancet 364: 35 - 40 (PubMed)
M. A Behr, S. A. Warren, H. Salamon, P. C. Hopewell, A. Ponce de Leon, C. L. Daley and P. M. Small. 1999. Transmission of Mycobacterium tuberculosis from Patients Smear-Negative for Acid-Fast Bacilli Lancet 353: 444 - 49 (PubMed)
M. W. Borgdorff, N. J. Nagelkerke, C. Dye and P. Nunn. 2000. Gender and Tuberculosis: A Comparison of Prevalence Surveys with Notification Data to Explore Sex Differences in Case Detection International Journal of Tuberculosis and Lung Disease 4: 123 - 32 (PubMed)
Bourdin Trunz, B., P. E. M. Fine, and C. Dye. Forthcoming. Global Impact of BCG Vaccination on Childhood Tuberculous Meningitis and Miliary Tuberculosis.
M. L. Brandeau, G. S. Zaric and A. Richter. 2003. Resource Allocation for Control of Infectious Diseases in Multiple Independent Populations: Beyond Cost-Effectiveness Analysis Journal of Health Economics 22: 575 - 98 (PubMed)
H. C. Bucher, L. E. Griffith, G. H. Guyatt, P. Sudre, M. Naef, P. Sendi and M. Battegay. 1999. Isoniazid Prophylaxis for Tuberculosis in HIV Infection: A Meta-Analysis of Randomized Controlled Trials AIDS 13: 501 - 7 (PubMed)
China Tuberculosis Control Collaboration. 2004. The Effect of Tuberculosis Control in China Lancet 364: 417 - 22 (PubMed)
N. J. M. Claessens, F. F. Gausi, S. Meijnen, M. M. Weismuller, F. M. Salaniponi and A. D. Harries. 2002. High Frequency of Tuberculosis in Households of Index TB Patients International Journal of Tuberculosis and Lung Disease 6: 266 - 69 (PubMed)
D. L. Cohn. 2003. Treatment of Latent Tuberculosis Infection Seminars in Respiratory Infections 18: 249 - 62 (PubMed)
Cohn, D. L., and W. M. El-Sadr. 2000. "Treatment of Latent Tuberculosis Infection." In Tuberculosis: A Comprehensive International Approach, ed. L. B. Reichman and E. S. Hershfield, 471-502. New York: Marcel Dekker.
G. W. Comstock. 2000. How Much Isoniazid Is Needed for Prevention of Tuberculosis among Immunocompetent Adults? In Reply International Journal of Tuberculosis and Lung Disease 4: 485 - 86 (PubMed)
G. W. Comstock, C. Baum and D. E. Snider. 1979. Isoniazid Prophylaxis among Alaskan Eskimos: A Final Report of the Bethel Isoniazid Studies American Review of Respiratory Disease 119: 827 - 30 (PubMed)
G. W. Comstock, V. T. Livesay and S. F. Woolpert. 1974. The Prognosis of a Positive Tuberculin Reaction in Childhood and Adolescence American Journal of Epidemiology 99: 131 - 38 (PubMed)
E. L. Corbett, S. Charalambous, V. M. Moloi, K. Fielding, A. D. Grant, C. Dye , et al. , et al.. 2004. Human Immunodeficiency Virus and the Prevalence of Undiagnosed Tuberculosis in African Gold Miners American Journal of Respiratory Critical Care Medicine 170: 673 - 79
E. L. Corbett, R. W. Steketee, F. O. ter Kuile, A. S. Latif, A. Kamali and R. J. Hayes. 2002. HIV-1/AIDS and the Control of Other Infectious Diseases in Africa Lancet 359: 2177 - 87 (PubMed)
E. L. Corbett, C. J. Watt, N. Walker, D. Maher, B. G. Williams, M. C. Raviglione and C. Dye. 2003. The Growing Burden of Tuberculosis: Global Trends and Interactions with the HIV Epidemic Archives of Internal Medicine 163: 1009 - 21 (PubMed)
C. Cuhadaroglu, M. Erelel, L. Tabak and Z. Kilicaslan. 2002. Increased Risk of Tuberculosis in Health Care Workers: A Retrospective Survey at a Teaching Hospital in Istanbul, Turkey BioMed Central Infectious Diseases 2: 14 (PubMed)
C. S. M. Currie, K. Floyd, B. G. Williams and C. Dye. 2005. Cost Affordability and Cost-Effectiveness of Strategies to Control Tuberculosis in Countries with High HIV, Prevalence BMC Public Health 5: 1 130 (PubMed)
E. de Jonghe, C. J. Murray, H. J. Chum, D. S. Nyangulu, A. Salomao and K. Styblo. 1994. Cost-Effectiveness of Chemotherapy for Sputum Smear-Positive Pulmonary Tuberculosis in Malawi, Mozambique and Tanzania International Journal of Health Planning and Management 9: 151 - 81 (PubMed)
D. G. de Viedma, M. Marin, S. Hernangomez, M. Diaz, M. J. R. Serrano, L. Alcala and E. Bouza. 2002. Reinfection Plays a Role in a Population Whose Clinical/Epidemiological Characteristics Do Not Favor Reinfection Archives of Internal Medicine 162: 1873 - 79 (PubMed)
Dholakia, R. 1996. The Potential Economic Benefits of the DOTS Strategy against TB in India. Geneva: World Health Organization.
T. M. Doherty, A. Demissie, J. Olobo, D. Wolday, S. Britton, T. Eguale , et al. , et al.. 2002. Immune Responses to the Mycobacterium tuberculosis-Specific Antigen ESAT-6 Signal Subclinical Infection among Contacts of Tuberculosis Patients Journal of Clinical Microbiology 40: 2 704 - 6 (PubMed)
L. Dudley, V. Azevedo, R. Grant, J. H. Schoeman, L. Dikweni and D. Maher. 2003. Evaluation of Community Contribution to Tuberculosis Control in Cape Town, South Africa International Journal of Tuberculosis and Lung Disease 7: Suppl. 1 S48 - 55 (PubMed)
C. Dye. 2000. Tuberculosis 2000-2010: Control, but Not Elimination International Journal of Tuberculosis and Lung Disease 4: Suppl. 2 S146 - 52 (PubMed)
C. Dye and M. A. Espinal. 2001. Will Tuberculosis Become Resistant to All Antibiotics? Proceedings of the Royal Society of London, Series B, Biological Sciences 268: 45 - 52
C. Dye, G. P. Garnett, K. Sleeman and B. G. Williams. 1998. Prospects for Worldwide Tuberculosis Control under the WHO DOTS Strategy Lancet 352: 1886 - 91 (PubMed)
C. Dye, S. Scheele, P. Dolin, V. Pathania and M. C. Raviglione. 1999. Global Burden of Tuberculosis: Estimated Incidence, Prevalence, and Mortality by Country Journal of the American Medical Association 282: 677 - 86 (PubMed)
C. Dye, C. J. Watt, D. M. Bleed, S. M. Hosseini and M. C. Raviglione. 2005. The Evolution of Tuberculosis Control, and Prospects for Reducing Incidence, Prevalence and Deaths Globally Journal of the American Medical Association 293: 2767 - 75 (PubMed)
C. Dye, C. J. Watt, D. M. Bleed and B. G. Williams. 2003. What Is the Limit to Case Detection under the DOTS Strategy for Tuberculosis Control? Tuberculosis 83: 35 - 43 (PubMed)
C. Dye and B. G. Williams. 2000. Criteria for the Control of Drug-Resistant Tuberculosis Proceedings of the National Academy of Sciences USA 97: 8180 - 85
C. Dye, B. G. Williams, M. A. Espinal and M. C. Raviglione. 2002. Erasing the World's Slow Stain: Strategies to Beat Multidrug-Resistant Tuberculosis Science 295: 2042 - 46 (PubMed)
C. Dye, F. Zhao, S. Scheele and B. G. Williams. 2000. Evaluating the Impact of Tuberculosis Control: Number of Deaths Prevented by Short-Course Chemotherapy in China International Journal of Epidemiology 29: 558 - 64 (PubMed)
M. A. Espinal, A. Laszlo, L. Simonsen, F. Boulahbal, S. J. Kim, A. Reniero , et al. , et al.. 2001. Global Trends in Resistance to Antituberculosis Drugs New England Journal of Medicine 344: 1294 - 1303 (PubMed)
Fine, P. E. M. 2001. "BCG Vaccines and Vaccination." In Tuberculosis: A Comprehensive International Approach, ed. L. B. Reichman, and E. S. Hershfield, 503-24. New York: Marcel Dekker.
K. Floyd. 2003. Costs and Effectiveness: The Impact of Economic Studies on TB Control Tuberculosis (Edinburgh) 83: 187 - 200
K. Floyd, J. Skeva, T. Nyirenda, F. Gausi and F. Salaniponi. 2003. Cost and Cost-Effectiveness of Increased Community and Primary Care Facility Involvement in Tuberculosis Care in Lilongwe District, Malawi International Journal of Tuberculosis and Lung Disease 7: Suppl. 1 S29 - 37 (PubMed)
K. Floyd, D. Wilkinson and C. Gilks. 1997. Comparison of Cost Effectiveness of Directly Observed Treatment (DOT) and Conventionally Delivered Treatment for Tuberculosis: Experience from Rural South Africa British Medical Journal 315: 7 1407 - 11 (PubMed)
C. Fordham and J. M. Vuola. 2002. New Vaccines for the Prevention of Tuberculosis Clinical Infectious Diseases 35: 465 - 74 (PubMed)
T. R. Frieden, P. I. Fujiwara, R. M. Washko and M. A. Hamburg. 1995. Tuberculosis in New York City—Turning the Tide New England Journal of Medicine 333: 229 - 33 (PubMed)
T. Frieden, T. R. Sterling, S. S. Munsiff, C. J. Watt and C. Dye. 2003. Tuberculosis Lancet 362: 887 - 99 (PubMed)
G. Friedland, S. Karim, Q. Karim, U. Lalloo, C. Jack, N. Gandhi and W. El Sadr. 2004. Utility of Tuberculosis Directly Observed Therapy Programs as Sites for Access to and Provision of Antiretroviral Therapy in Resource-Limited Countries Clinical Infectious Diseases 38: Suppl. 5 S421 - 28 (PubMed)
U. Fruth and D. Young. 2004. Prospects for New TB Vaccines: Stop TB Working Group on TB Vaccine Development International Journal of Tuberculosis and Lung Disease 8: 151 - 55 (PubMed)
A. M. Garber and C. E. Phelps. 1997. Economic Foundations of Cost-Effectiveness Analysis Journal of Health Economics 16: 1 - 31 (PubMed)
J. R. Glynn, M. D. Yates, A. C. Crampin, B. M. Ngwira, F. D. Mwaungulu, G. F. Black , et al. , et al.. 2004. DNA Fingerprint Changes in Tuberculosis: Reinfection, Evolution, or Laboratory Error? Journal of Infectious Diseases 190: 1158 - 66 (PubMed)
N. P. Goonetilleke, H. McShane, C. M. Hannan, R. J. Anderson, R. H. Brookes and A. V. Hill. 2003. Enhanced Immunogenicity and Protective Efficacy against Mycobacterium tuberculosis of Bacilli Calmette-Guerin Vaccine Using Mucosal Administration and Boosting with a Recombinant Modified Vaccinia Virus Ankara Journal of Immunology 171: 1602 - 9
Grange, J. 2003. "Immunophysiology and Immunopathology." In Clinical Tuberculosis, 3rd ed., ed. P. D. O. Davies, 88-104. London: Arnold.
M. A. Hamid, E. Declercq, A. Van Deun and K. A. R. Saki. 2004. Gender Differences in Tuberculosis: A Prevalence Survey Done in Bangladesh International Journal of Tuberculosis and Lung Disease 8: 952 - 57 (PubMed)
E. Hernandez-Garduno, V. Cook, D. Kunimoto, R. K. Elwood, W. A. Black and J. M. FitzGerald. 2004. Transmission of Tuberculosis from Smear Negative Patients: A Molecular Epidemiology Study Thorax 59: 286 - 90 (PubMed)
M. A. Horwitz, G. Harth, B. J. Dillon and S. Maslesa-Galic. 2000. Recombinant Bacillus Calmette-Guerin (BCG) Vaccines Expressing the Mycobacterium tuberculosis 30-kDA Major Secretory Protein Induce Greater Protective Immunity against Tuberculosis Than Conventional BCG Vaccines in a Highly Susceptible Animal Model Proceedings of the National Academy of Sciences USA 97: 13853 - 58
P. Hudelson. 1996. Gender Differentials in Tuberculosis: The Role of Socio-Economic and Cultural Factors Tubercle and Lung Disease 77: 391 - 400 (PubMed)
W. Jack. 2001. The Public Economics of Tuberculosis Control Health Policy 57: 79 - 96 (PubMed)
Jamison, D. T., W. H. Mosley, A. R. Meashem, and J. L. Bobadilla. 1993. Disease Control Priorities in Developing Countries. New York: Oxford University Press.
I. S. Johansen, B. Lundgren, A. Sosnovskaja and V. O. Thomsen. 2003. Direct Detection of Multidrug-Resistant Mycobacterium tuberculosis in Clinical Specimens in Low- and High-Incidence Countries by Line Probe Assay Journal of Clinical Microbiology 41: 9 4454 - 56 (PubMed)
J. L. Johnson, A. Okwera, D. L. Hom, H. Mayanja, C. Mutuluuza Kityo, P. Nsubuga , et al. , et al.. 2001. Duration of Efficacy of Treatment of Latent Tuberculosis Infection in HIV-Infected Adults AIDS 15: 2137 - 47 (PubMed)
W. Krebs. 1930. Die Falle von Lungentuberkulose in der aargauischen Heilstatte Barmelweid aus den Jahren 1912-1927 Beitrage zur Klinik der Tuberkulose 74: 345 - 79
I. Kristensen, P. Aaby and H. Jensen. 2000. Routine Vaccinations and Child Survival: Follow Up Study in Guinea-Bissau, West Africa British Medical Journal 321: 1435 - 38 (PubMed)
N. L. Letvin, B. R. Bloom and S. L. Hoffman. 2001. Prospects for Vaccines to Protect against AIDS, Tuberculosis, and Malaria Journal of the American Medical Association 285: 606 - 11 (PubMed)
T. Lietman and S. M. Blower. 2000. Potential Impact of Tuberculosis Vaccines as Epidemic Control Agents Clinical Infectious Diseases 30: Suppl. 3 S316 - 22 (PubMed)
B. J. Marais, R. P. Gie, H. S. Schaaf, A. C. Hesseling, C. C. Obihara, L. J. Nelson , et al. , et al.. 2004. The Clinical Epidemiology of Childhood Pulmonary Tuberculosis: A Critical Review of Literature from the Pre-Chemotherapy Era International Journal of Tuberculosis and Lung Disease 8: 278 - 85 (PubMed)
G. B. Marks, J. Bai, G. J. Stewart, S. E. Simpson and E. A. Sullivan. 2001. Effectiveness of Postmigration Screening in Controlling Tuberculosis among Refugees: A Historical Cohort Study, 1984-1998 American Journal of Public Health 91: 1797 - 99 (PubMed)
D. N. McMurray. 2003. Recent Progress in the Development and Testing of Vaccines against Human Tuberculosis International Journal of Parasitology 33: 547 - 54 (PubMed)
D. Menzies, M. J. Dion, B. Rabinovitch, S. Mannix, P. Brassard and K. Schwartzman. 2004. Treatment Completion and Costs of a Randomized Trial of Rifampin for 4 Months versus Isoniazid for 9 Months American Journal of Respiratory and Critical Care Medicine 170: 445 - 49 (PubMed)
G. Moalosi, K. Floyd, J. Phatshwane, T. Moeti, N. Binkin and T. Kenyon. 2003. Cost-Effectiveness of Home-Based Care versus Hospital Care for Chronically Ill Tuberculosis Patients, Francistown, Botswana International Journal of Tuberculosis and Lung Disease 7: Suppl. 1 S80 - 85 (PubMed)
C. J. L. Murray, E. de Jonghe, H. J. Chum, D. S. Nyangulu, A. Salomao and K. Styblo. 1991. Cost Effectiveness of Chemotherapy for Pulmonary Tuberculosis in Three Sub-Saharan African Countries Lancet 338: 1305 - 8 (PubMed)
C. J. L. Murray and J. A. Salomon. 1998. Modeling the Impact of Global Tuberculosis Control Strategies Proceedings of the National Academy of Sciences USA 95: 13881 - 86
A. Mwinga, M. Hosp, P. Godfrey-Faussett, M. Quigley, P. Mwaba, B. N. Mugala , et al. , et al.. 1998. Twice Weekly Tuberculosis Preventive Therapy in HIV Infection in Zambia AIDS 12: 2447 - 57 (PubMed)
L. J. Nelson and C. D. Wells. 2004. Global Epidemiology of Childhood Tuberculosis International Journal of Tuberculosis and Lung Disease 8: 636 - 47 (PubMed)
B. E. Neuenschwander, M. Zwahlen, S. J. Kim, E. G. Lee and H. L. Rieder. 2002. Determination of the Prevalence of Infection with Mycobacterium tuberculosis among Persons Vaccinated against Bacillus Calmette-Guerin in South Korea American Journal of Epidemiology 155: 654 - 63 (PubMed)
K. Noertjojo, C. M. Tam, S. L. Chan, J. Tan and M. Chan-Yeung. 2002. Contact Examination for Tuberculosis in Hong Kong Is Useful International Journal of Tuberculosis and Lung Disease 6: 19 - 24 (PubMed)
D. S. Nyangulu, A. D. Harries, C. Kang'ombe, A. E. Yadidi, K. Chokani, T. Cullinan , et al. , et al.. 1997. Tuberculosis in a Prison Population in Malawi Lancet 350: 1284 - 87 (PubMed)
D. Okello, K. Floyd, F. Adatu, R. Odeke and G. Gargloni. 2003. Cost and Cost-Effectiveness of Community-Based Care in Rural Uganda International Journal of Tuberculosis and Lung Disease 7: Suppl. 1 S72 - 79 (PubMed)
M. Pai, L. W. Riley and J. M. Colford. 2004. Interferon-gamma Assays in the Immunodiagnosis of Tuberculosis: A Systematic Review Lancet Infectious Diseases 4: 12 761 - 76 (PubMed)
PRC (People's Republic of China) Ministry of Health. 2000. Report on Nationwide Random Survey for the Epidemiology of Tuberculosis in 2000. Beijing: PRC Ministry of Health.
M. A. Quigley, A. Mwinga, M. Hosp, I. Lisse, D. Fuchs, J. D. H. Porter and P. Godfrey-Faussett. 2001. Long-Term Effect of Preventive Therapy for Tuberculosis in a Cohort of HIV-Infected Zambian Adults AIDS 15: 215 - 22 (PubMed)
S. Radhakrishna, T. R. Frieden and R. Subramani. 2003. Association of Initial Tuberculin Sensitivity, Age, and Sex with the Incidence of Tuberculosis in South India: A 15-Year Follow-Up International Journal of Tuberculosis and Lung Disease 7: 1083 - 91 (PubMed)
S. G. Reed, M. R. Alderson, W. Dalemans, Y. Lobet and Y. A. W. Skeiky. 2003. Prospects for a Better Vaccine against Tuberculosis Tuberculosis 83: 213 - 19 (PubMed)
M. Richardson, N. M. Carroll, E. Engelke, G. D. Van Der Spuy, F. Salker, Z. Munch , et al. , et al.. 2002. Multiple Mycobacterium Tuberculosis Strains in Early Cultures from Patients in a High-Incidence Community Setting Journal of Clinical Microbiology 40: 2750 - 54 (PubMed)
Rieder, H. L. 1999. "Epidemiologic Basis of Tuberculosis Control." Paris: International Union against Tuberculosis and Lung Disease.
———. 2003. "BCG Vaccines." In Clinical Tuberculosis, 3rd ed., ed. P. D. O. Davies, 337-53. London: Arnold.
H. L. Rieder, D. E. Snider and G. M. Cauthen. 1990. Extrapulmonary Tuberculosis in the United States American Review of Respiratory Disease 141: 347 - 51 (PubMed)
R. W. Shafer and B. R. Edlin. 1996. Tuberculosis in Patients Infected with Human Immunodeficiency Virus: Perspective on the Past Decade Clinical Infectious Diseases 22: 683 - 704 (PubMed)
M. V. Shilova and C. Dye. 2001. The Resurgence of Tuberculosis in Russia Philosophical Transactions of the Royal Society of London, Series B, Biological Sciences 356: 1069 - 75
E. Sinanovic, K. Floyd, L. Dudley, V. Azevedo, R. Grant and D. Maher. 2003. Cost and Cost-Effectiveness of Community-Based Care for Tuberculosis in Cape Town, South Africa International Journal of Tuberculosis and Lung Disease 7: Suppl. 1 S56 - 62 (PubMed)
P. Sonnenberg, J. R. Glynn, K. Fielding, J. Murray, P. Godfrey-Faussett and S. Shearer. 2005. How Soon after Infection with HIV Does the Risk of Tuberculosis Start to Increase? A Retrospective Cohort Study in South African Gold Miners Journal of Infectious Diseases 191: 150 - 58 (PubMed)
Styblo, K. 1991. Epidemiology of Tuberculosis. 2nd ed. The Hague: Royal Netherlands Tuberculosis Association.
P. G. Suarez, K. Floyd, J. Portocarrero, E. Alarcon, E. Rapiti, G. Ramos , et al. , et al.. 2002. Feasibility and Cost-Effectiveness of Standardised Second-Line Drug Treatment for Chronic Tuberculosis Patients: A National Cohort Study in Peru Lancet 359: 1980 - 89 (PubMed)
P. G. Suarez, C. J. Watt, E. Alarcon, J. Portocarrero, D. Zavala, R. Canales , et al. , et al.. 2001. The Dynamics of Tuberculosis in Response to 10 Years of Intensive Control Effort in Peru Journal of Infectious Diseases 184: 473 - 78 (PubMed)
Sutherland, I. 1968. "The Ten-Year Incidence of Clinical Tuberculosis Following `Conversion' in 2,550 Individuals Aged 14 to 19 Years." Unpublished progress report of the Tuberculosis Surveillance and Research Unit, KNCV, The Hague, Netherlands.
———1976. Recent Studies in the Epidemiology of Tuberculosis, Based on the Risk of Being Infected with Tubercle Bacilli Advances in Tuberculosis Research 19: 1 - 63 (PubMed)
I. Sutherland, E. Svandova and S. Radhakrishna. 1982. The Development of Clinical Tuberculosis Following Infection with Tubercle Bacilli: 1. A Theoretical Model for the Development of Clinical Tuberculosis Following Infection, Linking from Data on the Risk of Tuberculosis Infection and the Incidence of Clinical Tuberculosis in the Netherlands Tubercle 63: 255 - 68 (PubMed)
Tan-Torres Edejer, T., R. Baltussen, T. Adam, R. Hutubessy, A. Acharya, D. B. Evans, and C. J. L. Murray, eds. 2004. WHO Guide to Cost-Effectiveness Analysis. Geneva: World Health Organization.
Terris-Prestholt, F., and L. Kumaranayake. 2003. "Cost Analysis of the Zambian ProTEST Project: A Package to Reduce the Impact of Tuberculosis and Other HIV-Related Diseases." Unpublished report, London School of Hygiene and Tropical Medicine.
Toman, K. 1979. Tuberculosis Case-Finding and Chemotherapy. Questions and Answers. Geneva: World Health Organization.
M. Uplekar, V. Pathania and M. Raviglione. 2001. Private Practitioners and Public Health: Weak Links in Tuberculosis Control Lancet 358: 912 - 16 (PubMed)
A. van Rie, R. Warren, M. Richardson, T. C. Victor, R. P. Gie, D. A. Enarson , et al. , et al.. 1999. Exogenous Reinfection as a Cause of Recurrent Tuberculosis after Curative Treatment New England Journal of Medicine 341: 1174 - 79 (PubMed)
A. Vassall, S. Bagdadi, H. Bashour, H. Zaher and P. V. Maaren. 2002. Cost-Effectiveness of Different Treatment Strategies for Tuberculosis in Egypt and Syria International Journal of Tuberculosis and Lung Disease 6: 1083 - 90 (PubMed)
S. Verver, R. M. Warren, Z. Munch, E. Vynnycky, P. D. van Helden, M. Richardson , et al. , et al.. 2004. Transmission of Tuberculosis in a High Incidence Urban Community in South Africa International Journal of Epidemiology 33: 351 - 57 (PubMed)
E. Vynnycky and P. E. M. Fine. 1997. The Natural History of Tuberculosis: The Implications of Age-Dependent Risks of Disease and the Role of Reinfection Epidemiology and Infection 119: 183 - 201 (PubMed)
———2000. Life Time Risks, Incubation Period, and Serial Interval of Tuberculosis American Journal of Epidemiology 152: 247 - 63 (PubMed)
C. C. Whalen, J. L. Johnson, A. Okwera, D. L. Hom, R. Huebner, P. Mugyenyi , et al. , et al.. 1997. A Trial of Three Regimens to Prevent Tuberculosis in Ugandan Adults Infected with the Human Immunodeficiency Virus New England Journal of Medicine 337: 801 - 8 (PubMed)
WHO (World Health Organization). 2001. Vaccine Preventable Diseases: Monitoring System—2001 Global Summary. Geneva: WHO, Department of Vaccines and Biologicals.
———. 2002a. An Expanded DOTS Framework for Effective Tuberculosis Control. Geneva: WHO.
———. 2002b. The World Health Report: Reducing Risks, Promoting Healthy Life. Geneva: WHO.
———. 2004a. Anti-Tuberculosis Drug Resistance in the World. Report 3. Geneva: WHO.
———. 2004b. Cost and Cost-Effectiveness of Public-Private Mix DOTS: Evidence from Two Pilot Projects in India. Geneva: WHO.
———. 2004c. Global Tuberculosis Control: Surveillance, Planning, Financing. Geneva: WHO.
———. 2004d. Public-Private Mix for DOTS: Global Progress. Geneva: WHO.
———. 2004e. Respiratory Care in Primary Care Services—A Survey in 9 Countries. Geneva: WHO.
———. 2004f. World Health Report 2004: Changing History. Geneva: WHO.
———. 2005. Global Tuberculosis Control: Surveillance, Planning, Financing. Geneva: WHO.
D. Wilkinson, K. Floyd and C. F. Gilks. 1997. Costs and Cost-Effectiveness of Alternative Tuberculosis Management Strategies in South Africa—Implications for Policy South African Medical Journal 87: 4 451 - 55 (PubMed)
D. Wilkinson, S. B. Squire and P. Garner. 1998. Effect of Preventive Treatment for Tuberculosis in Adults Infected with HIV: Systematic Review of Randomised Placebo Controlled Trials British Medical Journal 317: 625 - 29 (PubMed)
B. G. Williams and C. Dye. 2003. Antiretroviral Drugs for Tuberculosis Control in the Era of HIV/AIDS Science 301: 1535 - 37 (PubMed)
G. L. Woods. 2001. Molecular Techniques in Mycobacterial Detection Archives of Pathology and Laboratory Medicine 125: 1 122 - 26 (PubMed)
D. B. Young and G. R. Stewart. 2002. Tuberculosis Vaccines British Medical Bulletin 62: 73 - 86 (PubMed)
